All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

  TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

When can we safely discontinue interferon alpha therapy in patients with MPN?

Featured:

Jean-Jacques KiladjianJean-Jacques Kiladjian

Dec 17, 2020


During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to the Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR. We asked, When can we safely discontinue interferon alpha therapy in patients with myeloproliferative neoplasms?

When can we safely discontinue interferon alpha therapy in patients with MPN?

Kiladjian reports the results of a study comparing the clinical outcome of patients with myeloproliferative neoplasms who discontinued therapy after at least three months of interferon alpha treatment to patients who continued interferon alpha treatment despite achieving a complete hematological remission.